Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)

1990-472X

Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации

11007

10.18499/1990-472X-2025-26-3-31-44

Study of endothelial dysfunction in patients with acute myeloid leukemia during chemotherapeutic treatment

Chibashova

Angelica Vladimirovna

Assistant Professor of Hospital Therapy with courses in Hematology and Transfusiologya.v.antipova@samsmu.ruGergel

Julia Анатольевна

PhD, Associate Professor of the Department of Hospital Therapy with courses in hematology and transfusiologyyu.a.gergel@samsmu.ruDavydkin

Igor Leonidovich

MD, Professor, Head of the Department of Hospital Therapy with courses in hematology and transfusiologyi.l.davydkin@samsmu.ru

FGBOU HE SamSMU of the Ministry of Health of Russia

10112025

2633144

02102025

2025

A common complication of anthracycline therapy in patients with acute myeloid leukemia is the development of cardiovascular toxicity. Endothelial dysfunction is one of the pathogenetic mechanisms of cardiovascular disease development, which is why there is interest in its assessment in clinical practice. The aim of the study was to assess endothelial dysfunction in patients with acute myeloid leukemia during chemotherapy. Materials and methods: The study included 110 patients with newly diagnosed acute myeloid leukemia who were prescribed polychemotherapy with anthracycline drugs. Patients were divided into groups based on the detection of cardiovascular toxicity, defined as a decrease in global longitudinal deformation of the left ventricle by more than 15%. All patients underwent assessment of endothelial damage biomarker levels (endothelin-1, asymmetric dimethylarginine) and laser Doppler flowmetry parameters during the study. Results: In patients with acute myeloid leukemia, signs of endothelial dysfunction are determined during chemotherapy with anthracycline drugs, which is manifested by an increase in the concentration of endothelial damage biomarkers (endothelin-1 and asymmetric dimethylarginine) and a decrease in microcirculation parameters assessed using laser Doppler flowmetry (microcirculation index, blood flow variation coefficient, amplitudes of myogenic and endothelial vasomotions and blood flow fluctuations associated with cardiac rhythms; results of respiratory and occlusion tests). Correlation relationships were revealed between the levels of endothelial biomarkers and laser Doppler flowmetry parameters in patients of the study group. Conclusion: Patients with acute myeloid leukemia receiving chemotherapy with anthracycline drugs show signs of endothelial dysfunction. Evaluation of microcirculation parameters using laser Doppler flowmetry is an accessible and reliable method for early detection of endothelial dysfunction.

acute myeloid leukemia, anthracycline drugs, cardiotoxicity, endothelial dysfunction, laser Doppler flowmetry, endothelin-1, asymmetric dimethylarginine.

острые миелоидные лейкозы, антрациклиновые препараты, кардиотоксичность, эндотелиальная дисфункция, лазерная допплеровская флуометрия, эндотелин-1, асимметричный диметиларгинин

1. Васюк Ю.А., Гендлин Г.Е., Емелина Е.И., Шупенина Е.Ю., Баллюзек М.Ф., Баринова И.В. и др. Согласованное мнение Российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии. Российский кардиологический журнал. 2021;26(9):4703. https://doi.org/10.15829/1560-4071-2021-4703

2. Suh E, Stratton KL, Leisenring WM, Nathan PC, Ford JS, Freyer DR et al. Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol. 2020 Mar;21(3):421-435. https://doi.org/10.1016/S1470-2045(19)30800-9. Epub 2020 Feb 14. PMID: 32066543; PMCID: PMC7392388.

3. Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013 Dec 15;112(12):1980-4. https://doi.org/ 10.1016/j.amjcard.2013.08.026. Epub 2013 Sep 25. PMID: 24075281.

4. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M et al. ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 Sep 21;37(36):2768-2801. doi: 10.1093/eurheartj/ehw211. Epub 2016 Aug 26. Erratum in: Eur Heart J. 2018 Mar 7;39(10):839. doi: 10.1093/eurheartj/ehw562. PMID: 27567406.

5. Васюк Ю.А., Гендлин Г.Е., Емелина Е.И., Шупенина Е.Ю., Баллюзек М.Ф., Баринова И.В. и др. Согласованное мнение Российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии. Российский кардиологический журнал. 2021;26(9):4703. https://doi.org/10.15829/1560-4071-2021-4703

6. Васюк Ю.А., Шупенина Е.Ю., Носова А.Г., Новосел Е.О., Выжигин Д.А. Вазотоксические эффекты противоопухолевой терапии: обзор современных данных. Рациональная Фармакотерапия в Кардиологии. 2023;19(2):203-208. https://doi.org/10.20996/1819-6446-2023-03-03

7. Dillon HT, Foulkes SJ, Baik AH, Scott JM, Touyz RM, Herrmann J et al. Cancer Therapy and Exercise Intolerance: The Heart Is But a Part: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2024 Jun 4;6(4):496-513. doi: 10.1016/j.jaccao.2024.04.006. PMID: 39239327; PMCID: PMC11372306.

8. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229-4361. https://doi.org/10.1093/eurheartj/ehac244.

9. Wang L, Cheng CK, Yi M, Lui KO, Huang Y. Targeting endothelial dysfunction and inflammation. J Mol Cell Cardiol. 2022 Jul;168:58-67. doi: 10.1016/j.yjmcc.2022.04.011. Epub 2022 Apr 20. PMID: 35460762.

10.

10. Krishnarao K, Bruno KA, Di Florio DN, Edenfield BH, Whelan ER, Macomb LP et al. Upregulation of Endothelin-1 May Predict Chemotherapy-Induced Cardiotoxicity in Women with Breast Cancer. J Clin Med. 2022 Jun 20;11(12):3547. doi: 10.3390/jcm11123547. PMID: 35743613; PMCID: PMC9224558.

11.

11. Finkelman BS, Putt M, Wang T, Wang L, Narayan H, Domchek S et al. Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. J Am Coll Cardiol. 2017 Jul 11;70(2):152-162. doi: 10.1016/j.jacc.2017.05.019. Erratum in: J Am Coll Cardiol. 2017 Nov 28;70(21):2738. doi: 10.1016/j.jacc.2017.10.041. PMID: 28683962; PMCID: PMC5665653.

12.

12. Sutterfield SL, Caldwell JT, Post HK, Lovoy GM, Banister HR, Ade CJ. Lower cutaneous microvascular reactivity in adult cancer patients receiving chemotherapy. J Appl Physiol (1985). 2018 Oct 1;125(4):1141-1149. doi: 10.1152/japplphysiol.00394.2018. Epub 2018 Aug 9. PMID: 30091663.

13.

13. Hazim AZ, Nhola LF, Villarraga HR, Patel SR, Sandhu N, Lerman A et al. Peripheral endothelial function changes during HER2-directed therapy differ based on whether or not a patient receives anthracycline. J Clinical Oncology, 38(15 Suppl), 1044.

14.

14. Гиматдинова Г. Р., Данилова О. Е., Давыдкин И. Л., Антипова А. В. Особенности микроциркуляции у пациентов с впервые выявленными индолентными неходжкинскими лимфомами с отягощенным сердечно-сосудистым анамнезом // Бюллетень медицинской науки, 2022, №2. C. 37-42. https://doi.org/DOI: 10.31684/25418475_2022_2_37

15.

15. Крупаткин А.И. Колебания кровотока - новый диагностический язык в исследовании микроциркуляции. Регионарное кровообращение и микроциркуляция. 2014;13(1):83-99. https://doi.org/10.24884/1682-6655-2014-13-1-83-99

16.

16. Бархатов И.В. Применение лазерной допплеровской флоуметрии для оценки нарушений системы микроциркуляции крови человека // Казанский медицинский журнал. - 2014. - Т. 95. - №1. C. 63-69. https://doi.org/10.17816/KMJ1458